WCLC 2025 - Posters & ePosters-P1.11.08 Peripheral Inflammatory Biomarkers Predict Immunotherapy Retreatment Outcomes in Advanced NSCLC

Pdf Summary

This retrospective study investigated biomarkers predicting outcomes of immune checkpoint inhibitor (ICI) retreatment in 113 advanced non-small cell lung cancer (NSCLC) patients treated at Shanghai Jiao Tong University between 2016 and 2022. While ICI rechallenge is a promising strategy for advanced NSCLC, identifying patients most likely to benefit remains challenging due to a lack of reliable predictive biomarkers.<br /><br />The study evaluated clinical features, PD-L1 expression, immune-related adverse events (irAEs), and peripheral inflammatory markers, focusing on the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI). Results showed that longer progression-free survival after initial immunotherapy (PFS1) significantly correlated with improved overall survival following ICI retreatment (OS2) and was a strong predictor of response to retreatment. The presence of irAEs during retreatment was associated with better PFS2 and OS2 outcomes, with severe irAEs providing additional survival benefits.<br /><br />Importantly, a combined low SII-PNI score, integrating systemic inflammation and nutritional status, predicted longer OS2 and independently prognosticated ICI retreatment outcomes. In contrast, elevated inflammatory markers indicated worsened prognosis, suggesting that systemic inflammation may reduce the efficacy of immunotherapy.<br /><br />The findings highlight the novel combined SII-PNI score as a clinically meaningful biomarker to improve risk stratification and guide personalized treatment decisions in NSCLC patients undergoing ICI retreatment. By capturing both inflammatory and nutritional status in one metric, the SII-PNI score could aid clinicians in optimizing immunotherapy strategies and ultimately enhance patient outcomes in this evolving therapeutic context.

Asset Subtitle

Jiaxin Zhong

Meta Tag

Speaker Jiaxin Zhong

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immune checkpoint inhibitor retreatment

non-small cell lung cancer

biomarkers

systemic immune-inflammation index

prognostic nutritional index

immune-related adverse events

progression-free survival

overall survival

inflammation and nutrition

risk stratification